by Market Overview:
The cancer cell market, valued at US$ 8,525.5 million in 2022, is estimated to reach US$ 12.36 Bn by 2030, exhibiting a CAGR of 8.20% over the forecast period. This market offers technologies for research on cancer development and progression, drug discovery and precision medicine approaches.
Market Dynamics:
Increasing adoption of immunotherapy drugs and rising orphan drug designations for rare cancers are fueling the market growth. Immunotherapy drugs trigger the body’s immune system to help detect and destroy cancer cells. Growing approval of chimeric antigen receptor (CAR) T-cell therapy for blood cancers and early-stage clinical evaluation of CAR-modified NK cells or macrophages to target solid tumors are also propelling the market forward. Moreover, high prevalence of cancer worldwide is anticipated to drive significant demand for novel targeted therapies and immunotherapies in the coming years.
Market Key Trends:
The global cancer cell market is witnessing increasing R&D investments for developing targeted therapies and immunotherapies. Manufacturers are investing heavily in cell engineering technologies to develop altered cell lines that can specifically target cancer cells. Additionally, growing adoption of single-cell analysis techniques for precision oncology is also driving the market. Single-cell analysis helps gain better insights into tumor heterogeneity and identify new drug targets at single-cell resolution.
SWOT Analysis:
Strengths: Wide applications in cancer research, drug development and testing. Growing R&D investments in cell engineering technologies.
Weaknesses: High costs associated with cell line development and maintenance. Challenges in standardizing cell-based assays.
Opportunities: Emerging areas like stem cell therapy and CAR T-cell therapy offer significant growth potential. Rising popularity of organ-on-chip models for preclinical testing.
Threats: Stringent regulatory pathways for clinical applications. Impact of COVID-19 on laboratory research.
Key Takeaways:
The Global Cancer Cell Market Size was valued at US$ 8,525.5 million in 2022 and is expected to reach over US$ 15 billion by 2030, expanding at a CAGR of 8.20% during the forecast period. The increasing prevalence of cancer worldwide due to changing lifestyles and growing geriatric population is a key factor driving the market.
By cell type, the mammary cancer cell segment dominated the market in 2022 due to high research focus on breast cancer biology. Breast cancer being the most common cancer in women globally has increased the research utilizing mammary cancer cell lines.
On the basis of regional analysis, North America dominated the cancer cell market in 2022. This was mainly attributed to high R&D investments from private and government sectors. However, Asia Pacific is anticipated to exhibit the fastest growth during 2021-2030 owing to rising cancer incidence, increasing biotechnology research spending, and growing outsourcing of clinical research to Asia Pacific countries.
Key players operating in the cancer cell market are Abbott Laboratories, Novartis International AG, Arcellx, Autolus Therapeutics, Kite Pharma, Cellectis, Celyad Oncology, Crescendo Biologics Limited, GammaDelta Therapeutics Ltd., Bio-Rad Laboratories Inc, QIAGEN Inc, Thermo Fisher Scientific, Merck Millipore, Siemens Healthineers AG, and GE Healthcare. These players are focusing on developing genetically engineered cancer cell lines for targeted therapies.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
